LOXO TRK 15003

Name No. For Patients with Purpose
LOXO TRK 15003 18-36

Paediatric advance solid or primary CNS tumours.

To determine the safety of oral LOXO-101 (larotrectinib) and to determine the overall response rate.


NB SCI Study

Name No. For Patients with Purpose
NB SCI Study 16-49

This is a registry study to collect patient data.